Hyperliquid Strategies Seeks $1 Billion to Bolster HYPE Treasury, Driving Token Rally
Hyperliquid Strategies, a pending merged entity involving Nasdaq-listed Sonnet BioTherapeutics and Rorschach I LLC, has filed an S-1 registration statement with the US Securities and Exchange Commission (SEC) to raise up to $1 billion. The funds will primarily be used to acquire more of the Hyperliquid (HYPE) token, which powers the world’s largest decentralized derivatives … Read more